A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
This is a multicenter, open-label, single-arm, phase II study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in patients with advanced HER2 negative breast cancer.
Breast Cancer
DRUG: Mitoxantrone Hydrochloride Liposome Injection
Objective response rate (ORR), To investigate the preliminary antitumor efficacy, From the enrollment to the final documentation of response of the last subject(assessed up to 36 months)
Disease control rate (DCR), To investigate the preliminary antitumor efficacy, From the enrollment to the final documentation of response of the last subject(assessed up to 36 months)|Duration of response (DoR), To investigate the preliminary antitumor efficacy, From the enrollment to death,lost to follow-up,withdrawal,or study end,whichever occurred first,assessed up to 36 months|Progression-free survival (PFS), To investigate the preliminary antitumor efficacy, From the enrollment to death,lost to follow-up,withdrawal,or study end,whichever occurred first,assessed up to 36 months|Overall survival (OS), To investigate the preliminary antitumor efficacy, From the enrollment to death,lost to follow-up,withdrawal,or study end,whichever occurred first,assessed up to 36 months|Treatment emergent adverse events (TEAEs), The incidence and severity of adverse events, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs)., from the administration of the first dose to 28 days after the last dose
This is a multicenter, open-label, single-arm, phase II study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in patients with advanced HER2 negative breast cancer. Eligible patients will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 21 days (q3w, 1 cycle) until disease progression, intolerable toxicity, death, or investigator or patient decision.